Home > News > Dabur Pharma eyes China & Japan entry
August 2nd, 2007
Dabur Pharma eyes China & Japan entry
Abstract:
Domestic anti-cancer drug major Dabur Pharma is finalising plans to enter Japan and China. The company has started the groundwork of filing drug applications and is scouting for potential pharma acquisitions in both the countries.
Dabur Pharma also plans to expand the range of products developed on its nanotechnology drug delivery system, christened ‘Nanoxel'. At the moment, it sells the popular anti-cancer drug ‘Paclitaxel' on this platform. "We also want to export this portfolio of drugs in US, Europe and South-east Asian markets," said Mr Vij.
Source:
economictimes.indiatimes.com
Bookmark:
| Related News Press |
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||